Recursion Pharmaceuticals, Inc. Class A Common Stock
RXRXRecursion Pharmaceuticals, Inc. Class A (RXRX) is a biotechnology company that leverages machine learning and automation to discover and develop new medicines. Founded with a focus on using data-driven approaches to accelerate drug discovery, Recursion combines high-throughput biology, AI, and computational science to identify potential therapeutic candidates across various diseases. The company aims to streamline the development process and improve success rates in bringing innovative treatments to market.
Company News
Recursion's Compensation Committee approved the grant of 3,234,866 inducement restricted stock units to 24 new employees on July 27, 2026, as part of its 2024 Inducement Equity Incentive Plan. The awards will vest quarterly over four years, subject to continued employment.
The article identifies three stocks with significant upside potential by end of 2026: CRISPR Therapeutics, expected to generate $40M in revenue this year and $160M+ next year as its Casgevy treatment gains traction; Microsoft, trading 40% below analyst price targets as management addresses cloud/AI business challenges; and Recursion Pharmaceutica...
The article argues that Recursion Pharmaceuticals and Sarepta Therapeutics, despite significant stock declines, remain unattractive investments. Recursion has no approved products and faces competition in AI-driven drug discovery. Sarepta struggles with safety concerns around its lead therapy Elevidys and faces an uncertain path to regaining mark...
The generative AI in drug discovery market is experiencing significant expansion, growing from $0.25 billion in 2025 to $0.33 billion in 2026, with projections to reach $0.86 billion by 2030 at a 27% CAGR. Key drivers include rising drug development costs, computational chemistry advancements, increased biological datasets, and strategic collabor...
Cathie Wood's Ark Invest actively purchased shares in Tesla, SoFi Technologies, and Recursion Pharmaceuticals on Thursday. Tesla delivered 480,126 vehicles in Q2, exceeding analyst expectations by 74,000 units, though the stock fell 7.35% on the day. SoFi, which Ark bought every trading day this week, continues to demonstrate strong growth metric...
